AIR Fate

anonymous

Guest
I am surprised there is nothing yet posted about the fate of this division. So, let’s hear it. The UTI med is slated for submission in 2025. Trelegy will be taking a huge financial hit with the $35 cap coming. Any thoughts on what this sales force has in store? Layoffs coming? Q3? Anyone have intel on what the UTI med chances are for approval?
 






Vacations is over but may still take two years before anyone will actually make a decision. Good run!! Every other big pharma figured it out years ago. Would say we stayed too long but have not had to work in years and just waiting for our package.
 






Vacations is over but may still take two years before anyone will actually make a decision. Good run!! Every other big pharma figured it out years ago. Would say we stayed too long but have not had to work in years and just waiting for our package.

The Dildo of Consequences rarely comes lubricated
 






AIR is slated to support UTI, gonorrhea, and
for 2026 Complicated and Refractory chronic cough. Trelegy had 9- million patients. How many patients are all these other therapies? 20,000 x 4 = maybe 80,000. That would require a fraction of the AIR Team. Some could go to Nucala as that team shift to other long acting anti-IL5. That’s my guess!